Gaithersburg-based Emergent BioSolutions will manufacture one of the first potential vaccines to fight the Zika virus, it announced Monday.
Under a federal contract, Emergent (NYSE: EBS) will develop and manufacture the vaccine for the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. Emergent will develop the vaccine material from a base created by an undisclosed private company, university or institution and provided by BARDA, officials said.
Kitchology, a food+wellness+tech startup headquartered in Germantown, was among the winners of this year’s Maryland Incubator Company of the Year (ICOY) Awards, winning in the consumer product category.
QIAGEN N.V. (Nasdaq: QGEN) announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
The University System of Maryland is hoping a new $25 million venture capital fund it established will help spin off more commercial businesses — with the system reaping the benefits in the long run.
Innovation Village, an effort to spur economic development in West Baltimore, is partnering with Howard County’s Conscious Venture Lab to help develop fledgling companies and entrepreneurs.
Qiagen and CosmosID have joined the Metagenomics and Metadesign of Subways and Urban Biomes (MetaSUB) consortium, an international five-year effort led by Weill Cornell Medicine, to map the genomes and epigenomes of microbial communities in 54 cities in 32 countries.
What is success? Is it the amount of money you have in your bank account, at any given point? Is it that feeling you get after delivering a killer presentation, or even a pretty decent bar joke? Or is it something bigger—something wholly unnamable, undefinable, immeasurable, and totally subjective?
Throughout the United States, innovation districts have been proposed with varying degrees of emphasis on inclusivity and opportunity. In January 2016, a public-private partnership representing many of Baltimore’s most influential anchor institutions, community-based organizations, and private companies declared their intent to develop an innovation district in West Baltimore dubbed the “Innovation Village.” This week, the Innovation Village steering committee announced several initiatives aimed at supporting inclusive economic growth in West Baltimore neighborhoods including free Wi-Fi, entrepreneurial assistance programs, and the development of a food hub.
Montgomery County is participating in an important regional initiative called the Global Cities Initiative aimed at helping our businesses export and connecting our local economy with the global market.
Nationally, this initiative is led by JP Morgan and the Brookings Institution. In the National Capital Region, it is a collaborative effort between the Greater Washington Board of Trade, the Metropolitan Washington Council of Governments, and the Consortium of Universities of the Washington Metropolitan Area and numerous other regional partners.
Awards season in the Baltimore tech scene moved into summer mode at the American Visionary Art Museum last week, where the Maryland Incubator Company of the Year Awards were handed out.
Baltimore incubators were well represented, with companies from the Emerging Technology Centers, Betamore and Johns Hopkins FastForward picking up honors.
Another week, another new initiative for IBM Watson Health.
Wednesday, IBM announced the formation of a Watson Health medical imaging collaborative, seeking to make “cognitive imaging” a routine part of medical practice in oncology, neurology, diabetes care, eye care, cardiovascular disease and other image-heavy specialties. “Imaging is one of the things that spans across many different areas,” said Anne Le Grand, IBM Watson Health’s vice president of imaging.
Join us for a thrilling evening of start-up pitches from multiple sectors in healthcare including: Services, Health IT, Biotechnology, Medical Devices and Diagnostics. Applications are still being accepted, so if you not afraid of getting nipped by one of our judges, send your information to jhausfeld@sopenet.org.
The Brexit votes have been counted. The Brits have decided to leave the European Union. And the financial markets are taking it hard. Right now, futures on the London stock exchange are down 8%. The pound is down 9.8 percent, more than double its previous record decline of 4.1 percent. We’re living in interesting times.
Thousand Oaks-based biotech giant Amgen has put its backing behind a new, life sciences incubator, called QB3@953. According to Amgen, it will provide a five year, platinum sponsorship of the San Francisco life sciences incubator, to accelerate the development of new therapies to improve human health. Financial details of the sponsorship were not detailed. As part of that sponsorship, Amgen said it will be providing two awards each year with a company receiving one year of lab space at QB3@953, in addition to connections to Amgen’s executives and other resources. QB3@953 provides lab space to life sciences startups, which Amgen says is a “key obstacle” for life sciences startups. A similar effort, the Ventura BioCenter, operates just around the corner from Amgen in the Thousand Oaks area.
Between June 2015 and June 2016, we’ve created more spaces and places for people to engage with the Science Center; honed and expanded our programs to support innovation and entrepreneurship; and enhanced the way we talk about our role in Greater Philadelphia’s innovation ecosystem.
The first proposed test of CRISPR gene-editing technology in human beings is being funded by Internet billionaire Sean Parker, MIT Technology Review has learned.
The novel cancer treatment, initially disclosed last week, is being reviewed Tuesday by a federal advisory panel in Washington, D.C., and could become the first clinical trial involving CRISPR, the red-hot gene modification technology.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
